Cowen and Company Reaffirms “Outperform” Rating for Humana Inc. (HUM)
Humana Inc. (NYSE:HUM)‘s stock had its “outperform” rating restated by investment analysts at Cowen and Company in a note issued to investors on Wednesday. They presently have a $275.00 target price on the insurance provider’s stock, up from their prior target price of $230.00. Cowen and Company’s price target points to a potential upside of 14.56% from the stock’s current price.
Several other equities analysts have also recently weighed in on HUM. UBS AG reissued a “neutral” rating and set a $237.00 price target (up from $205.00) on shares of Humana in a report on Wednesday, June 28th. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Morgan Stanley raised their target price on Humana from $269.00 to $276.00 and gave the stock an “overweight” rating in a report on Thursday, August 17th. Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $223.00 target price (up from $200.00) on shares of Humana in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $246.60.
Humana (HUM) traded down 0.30% during mid-day trading on Wednesday, reaching $239.32. The company’s stock had a trading volume of 1,258,265 shares. Humana has a 12-month low of $163.50 and a 12-month high of $259.76. The firm has a market cap of $34.59 billion, a PE ratio of 19.69 and a beta of 0.87. The company has a 50-day moving average price of $250.95 and a 200-day moving average price of $232.23.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating the consensus estimate of $3.08 by $0.41. The firm had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same period in the prior year, the firm earned $2.30 EPS. On average, equities research analysts expect that Humana will post $11.55 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Cowen and Company Reaffirms “Outperform” Rating for Humana Inc. (HUM)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/20/cowen-and-company-reaffirms-outperform-rating-for-humana-inc-hum.html.
In other news, insider William Kevin Fleming sold 3,071 shares of Humana stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the completion of the sale, the insider now owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the sale, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The disclosure for this sale can be found here. Insiders have sold 60,566 shares of company stock valued at $15,326,746 in the last ninety days. Insiders own 0.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Guardian Life Insurance Co. of America raised its stake in shares of Humana by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 4 shares in the last quarter. Reliance Trust Co. of Delaware increased its holdings in Humana by 0.7% during the second quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock valued at $270,000 after buying an additional 8 shares during the period. Creative Planning increased its holdings in Humana by 0.3% during the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock valued at $1,173,000 after buying an additional 15 shares during the period. WFG Advisors LP increased its holdings in Humana by 4.5% during the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after buying an additional 20 shares during the period. Finally, Cadence Capital Management LLC increased its holdings in Humana by 0.4% during the second quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock valued at $1,367,000 after buying an additional 22 shares during the period. 95.12% of the stock is owned by hedge funds and other institutional investors.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.